<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Liz Nunley on Medium]]></title>
        <description><![CDATA[Stories by Liz Nunley on Medium]]></description>
        <link>https://medium.com/@liznunley?source=rss-a0bfa12633fe------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*5KnHss-Rmzbp-RzZvSL9gQ.jpeg</url>
            <title>Stories by Liz Nunley on Medium</title>
            <link>https://medium.com/@liznunley?source=rss-a0bfa12633fe------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Tue, 17 Nov 2026 00:49:12 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@liznunley/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Chapter 2: Adding a few steps to “thinking outside the box”]]></title>
            <link>https://medium.com/@liznunley/chapter-2-adding-a-few-steps-to-thinking-outside-the-box-b9becba51065?source=rss-a0bfa12633fe------2</link>
            <guid isPermaLink="false">https://medium.com/p/b9becba51065</guid>
            <category><![CDATA[problem-solving]]></category>
            <category><![CDATA[box]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[human-centered-design]]></category>
            <category><![CDATA[creativity]]></category>
            <dc:creator><![CDATA[Liz Nunley]]></dc:creator>
            <pubDate>Fri, 26 Oct 2018 06:09:46 GMT</pubDate>
            <atom:updated>2018-10-26T06:09:46.329Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/788/1*9qljkqobtc2zNKEu3N9ZvQ.png" /><figcaption>Why even write a Medium post when Google basically sums up your point in 10 lines?</figcaption></figure><p>Growing up, I was always encouraged by teachers and mentors to “think outside the box”. This always felt like very vague, curt advice given in hopes of inspiring students to suddenly change their mindsets to “think creatively”. “Creativity” today is almost treated as this magic quality, straddling the gap between genius and thinker. Creativity has become a hot topic, something that we laud in schools, in companies, and in cultures. And yet, it still seems to evade a concrete or even consistent definition or test.</p><p>I recently listened to a <a href="http://freakonomics.com/podcast/creativity-1/">Freakanomics podcast</a> on creativity that gave me a useful working definition, defining creativity as “novelty that works”. By this simple definition, creativity is not just thinking outside the box for the sake of thinking outside the box, but doing it in a way <em>that produces something useful or helpful</em>. This attention to utility is something I often see overlooked here in Silicon Valley; there are a many companies that are “doing things outside the box”, but sometimes the thing they’re doing isn’t really significant or impactful. It seems that there are a number of companies that start with a “creative solution”, but they don’t necessarily know what problem they’re solving, and they go out searching for a problem. To put this in terms of boxes — they create a solution outside the box, before understanding if that box even needs to be broken down.</p><p>In the health world, we saw this pattern clearly around the drug development and clinical trial industry. Drug companies pump out variations of the same experimental therapy, but overlook the major issue, which is not that there are not enough new experimental therapies, but instead that there is not a working process for patients who could benefit from targeted therapies to find those therapies and vice versa. And so, what we’re left with is millions of dollars going into producing drugs that ultimately sit on a shelf somewhere waiting to find a home, or worse are put into clinical trials that eventually are shut down due to lack of accrual. This was summed up well in a <a href="https://www.nytimes.com/2017/08/12/health/cancer-drug-trials-encounter-a-problem-too-few-patients.html">New York Times article</a> titled simply: “Too Many Drug Trials, Too Few Patients”. In healthtech, we’d discuss this frequently in the context of the rise of genetic testing. Sure, it’s certainly a novel idea to have access to your DNA profile. Without the right expert analysis or support to digest these results, however, the utility is seriously called into question — and in fact, the undirected access to knowledge can <a href="https://www.nytimes.com/2018/09/15/opinion/sunday/23andme-ancestry-alzheimers-genetic-testing.html">lead to more harm than good</a>.</p><p>Overall, I find issue with the approach of favoring novelty over utility in regards to creativity in two ways; (1) there are so many real problems to be solved, that it seems crazy to waste any VC money or start-up time on orphan solutions, and (2) when you start with a solution, and not the problem, you’re inherently not practicing human-centered design, because you don’t even know who your customer is. Instead, we should start with the problem and the deeply understanding the people experiencing those problems. If I had to give advice on how to be creative my younger self, it would come as a four step process: (1) start by identifying a specific box, (2) find the people in that box and understand if it’s working, and if not, what their problems or frustrations are with the box, (3) understand why the box exists; who created the box? When was the box updated? Who controls the box?, and then and only then, (4) <em>think outside the box</em>.</p><p>At the startup where I worked, we did a good job of following this four step process at first. When I joined our “box” was the system by which people access clinical trials, focused on just lung cancer patients in the US and understanding their frustrations in not being able to find the best cutting-edge treatments. In this box, patients are forced to go to see a single physician at a single institution. As we started to understand why this was the norm, we could trace this process back to the early days of oncology. Imagine you are a cancer patient in the 1950’s. At this time, it makes sense for you to go to see one doctor, at one hospital. There are only a handful of chemotherapy option, so you’re doctor is capable of knowing each of them well. We haven’t yet processed the human genome, so we don’t know too much about your unique cancer biology. On top of all that, travel is expensive and time-intensive — so you probably wouldn’t travel to see a specialist anyway. Snap back to 2018. We have thousands of cancer drugs, surgeries, procedures and new protocol added every week. We have not only completed the Human Genome Project, but genomic testing has become somewhat mainstream with tests from <a href="https://www.foundationmedicine.com/">FoundationOne</a> and <a href="https://www.carislifesciences.com/">Caris</a>. We have hundreds of cancer centers, each running different clinical trials and with different medical experts. And on top of that, cross-country travel is somewhat affordable and possible in a single day.</p><p>So when you start to unpack why finding the right treatment is such a nightmare, you realize that it is an industry that fell pray to “this is the box we have to operate within, and <em>that’s just the way things are</em>” (or, overlooking step three of the four step process entirely). It was this foundation and understanding of the problem space that inspired the product development for cancer patients at my recent startup. We then applied many of the technologies and processes that we’ve become so accustomed to with companies like AirBnb, Kayak, and OpenTable for options searching and matching, and imagined a world in which consumers could experience the same ease in finding cancer treatments.</p><p>Since you know how this story ends, with a startup burning out, I’ll give a preview to the major theme of future chapters: unfortunately, creativity doesn’t equal success. Even the best creativity is not the only ingredient necessary to launch a successful business. In future chapters, I’ll talk about how creativity can clash with ego, and how sometimes being creative isn’t necessary, or even economical.</p><p><em>One more note</em>: In my last post, I praised hitting “publish” over drowning in a hole of editing and perfecting, which I still stick by. I did, however, receive a frantic text from my dear mother shortly after my first post commenting on my confusion of the spelling of “we’re” and “were”. So, there are limits to theory (3), I suppose.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b9becba51065" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[To start]]></title>
            <link>https://medium.com/@liznunley/to-start-22750e7a6322?source=rss-a0bfa12633fe------2</link>
            <guid isPermaLink="false">https://medium.com/p/22750e7a6322</guid>
            <category><![CDATA[launch]]></category>
            <category><![CDATA[startup]]></category>
            <category><![CDATA[cancer]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[culture]]></category>
            <dc:creator><![CDATA[Liz Nunley]]></dc:creator>
            <pubDate>Thu, 18 Oct 2018 23:22:36 GMT</pubDate>
            <atom:updated>2018-10-18T23:22:36.027Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*M5UbN2gvavJR7WIxKot-Dg.jpeg" /></figure><p>As the doors close on the much beloved project I have worked on for two and a half years, I have vowed to journal on the experience for a few reasons: first, first to share the somewhat horrifying revelations I’ve uncovered working in the healthcare industry, and second, to catalogue the invaluable lessons I’ve internalized from seeing the lifecycle of a company.</p><p>Back in 2016, I quit my previous job working for a big chain of cancer hospitals in search of a job that would still allow me to work inside the healthcare industry, but in an environment where I could move fast and have a significant impact. It was at this point that I found a small startup of about twenty people whose goal it was to help patients find the right life-prolonging therapies for their cancer.</p><p>Over the course of the two plus years working at this startup, I’d talk with friends about the major career and life decisions they we’re making, and inevitably business school would come up. This conversation always made me reflect upon the fact that I sincerely feel that I’ve been the best business school there is — being part of starting a company from the ground up. Unlike business school, however, I do no have text books or papers my future self can reference, I only have the memories and lessons I’ve picked up along the way, hence the journaling.</p><p>In addition, I <a href="https://medium.com/the-mission/the-accountability-effect-a-simple-way-to-achieve-your-goals-and-boost-your-performance-8a07c76ef53a">read</a> that your chances of achieving a goal go up by almost fifty percent if you write them down, and that percentage bumps up significantly if you share that goal with someone else to hold you accountable. So here I am, <strong>my goal is to journal the various nuggets of wisdom I have absorbed in building a company with the most dedicated, passionate team I’ve ever met</strong>— from the identification of a major problem, the birth of a solution, the false peaks of building a solution, and ultimately the flame of the solution burning out.</p><h4>Chapter 1: Boiling the ocean just gets you lukewarm water.</h4><p>Over the course of a few chapters, I will <em>succinctly </em>try<em> </em>explain what the startup was trying to do. Ironically, the difficulty in trying to explain what we do is probably one of the major contributors to why we ultimately didn’t succeed; we we’re simply trying to do too much. It seems like a simple lesson: stick with one problem, one solution, and keep your target audience tight. Yet, as you start going about serving people, you uncover a plethora of issues, and if you’re ambitious people, as we we’re, it can be tempting to start tackling these other problems all at once.</p><p>I particularly struggled with wanting to do it all, as I had seen the fractured healthcare system patients have to deal with; being forced to piece together their own care with one piece of the puzzle at a time, instead of having end-to-end solutions. In cancer, this often means that cancer patients and their families are left with the burdensome work of project management: coordinating appointments, calling doctors’ offices, collecting their own medical records, researching treatments, scheduling logistic, scheduling meal plans and babysitters, getting different specialists to communicate on their case…you get the point. The result is that cancer becomes a full-time job, and often things fall through the cracks. Because I had seen this world firsthand at the hospital where I previously worked, I wanted to be that end-to-end solution, the “one stop shop” for cancer.</p><p><strong>So let’s rewind to where it started</strong>.</p><p>When I joined the team in 2016, the company was focused on using genomic testing to find the right treatments for lung cancer patients in the United States. We would collect a sample of a patient’s tumor and blood, and run a genomic test to identify the driver mutations of their cancer, and based on those mutations identify the best clinical trials for these patients. So while I wouldn’t describe this product as “simple”, it was solving a specific problem — finding the right clinical trials, with one product — a genomic test, and was focused on a small target group — lung cancer patients.</p><p>Over the course of the next two years, the scope of our project exploded until we found ourselves trying to give <em>anyone</em> (healthy or with cancer) access to the best treatments (clinical trials and standard of care), anywhere in the world (with targeted audiences in the US and China), with a double-sided platform, including a mobile app for physicians and a mobile app for patients. It wasn’t until we developed this mammoth of a platform that we officially launched our product to the public (a mouthful elevator pitch!).</p><p>I take a few key things away from this and will unpack these in chapters to come (1) it’s indicative of a healthcare system for cancer patients so fractured, that we basically found ourselves creating an entirely new patient experience across each step on the path to treatment, (2) in doing so many things, we lost focus, and ended up doing everything with mediocrity — lukewarm, if you will, and finally, (3) we fell into the perfectionist trap of waiting <em>way</em> too long to launch, instead of launching with our small idea and letting our customers drive the direction of the product.</p><p>For now, that’s all. I am trying to take lesson (3) to heart with these articles; there is much to say and thousands of ways to tell the story, but I am choosing the path of somewhat polished train-of-thought.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=22750e7a6322" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>